Previous 10 | Next 10 |
2023-03-09 08:45:20 ET Silvergate Capital SI -36% on plans to wind down operations, liquidate Silvergate Bank . SVB Financial SIVB -28% on $1.25B stock offering, $500M depositary share offering . Arhaus ARHS -11% on Q4 earnings release . Altamira Th...
2023-03-09 07:12:36 ET Fulcrum Therapeutics press release ( NASDAQ: FULC ): Q4 GAAP EPS of -$0.50 misses by $0.01 . Revenue of $0.7M (-86.2% Y/Y) misses by $1.19M . As of December 31, 2022, cash, cash equivalents and marketable securities were $202.9 milli...
― Company is working to address clinical hold on the Investigational New Drug application for FTX-6058 for the potential treatment of sickle cell disease ― ― FTX-6058 data from 12 mg cohort of Phase 1b trial show clinically relevant fetal hemoglobin increases of up ...
2023-03-06 17:01:40 ET Gainers: ATA Creativity ( AACG ) +17% . WW International ( WW ) +7% . bluebird bio ( BLUE ) +3% . TuSimple Holdings ( TSP ) +3% . ACADIA Pharmaceuticals ( ACAD ) +3% . Losers: Cara...
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2022 finan...
Boston, Massachusetts--(Newsfile Corp. - March 6, 2023) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), a clinical-stage biopharmaceutical company based in...
ATLANTA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities laws. On February 24, 2023, Fulcrum announced that “on Feb...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s no doubt Fulcrum Therapeutics (NASDAQ: FULC ) is committed to advancing its proposed treatment for sickle cell disease. However, there’s a regulatory holdup . Fulcrum Therapeutics will attempt to work...
Fulcrum Therapeutics ( NASDAQ: FULC ) has plummeted 55% in Friday premarket trading after the US FDA placed a full clinical hold on its Investigational New Drug application for sickle cell disease treatment FTX-6058. The hold is due to previouslhy reported preclinical data. As a r...
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that on February 23, 2023, the U.S. Food and Drug Admi...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...